ciprofloxacin has been researched along with Anthrax in 142 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Anthrax: An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax." | 8.82 | US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. ( Albrecht, R; Dionne, P; Higgins, K; Meyer, JM; Meyerhoff, A; Murphy, D, 2004) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 8.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis." | 7.96 | Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax. ( Blanchard, JD; Crichton, M; Jager, S; Stratilo, CW, 2020) |
| " The current standard of care for inhalational anthrax postexposure prophylaxis is ciprofloxacin therapy twice daily for 60 days." | 7.74 | Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. ( Arhin, FF; Bassett, A; Bassett, J; Heine, HS; Ivins, BE; Lehoux, D; Miller, L; Moeck, G; Parr, TR, 2008) |
| "In August 2000, the US Food and Drug Administration (FDA) approved ciprofloxacin hydrochloride (Cipro; Bayer) for management of postexposure inhalational anthrax." | 4.82 | US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. ( Albrecht, R; Dionne, P; Higgins, K; Meyer, JM; Meyerhoff, A; Murphy, D, 2004) |
| "In the clindamycin group, 8 of 11 (73%) survived demonstrating its efficacy for the first time in inhalational anthrax, compared to 9 of 9 (100%) with ciprofloxacin, and 8 of 11 (73%) with ciprofloxacin + clindamycin." | 4.02 | Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin. ( Barr, JR; Boyer, AE; Chabot, DJ; Cote, CK; Fetterer, DP; Friedlander, AM; Ingavale, S; Klimko, CP; Miller, JA; Schellhase, CW; Somerville, BC; Tobery, SA; Twenhafel, NA; Vietri, NJ; Woolfitt, AR; Wright, ME, 2021) |
| "The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis." | 3.96 | Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax. ( Blanchard, JD; Crichton, M; Jager, S; Stratilo, CW, 2020) |
| "The aim of this study was to compare the pharmacokinetics and efficacy of ciprofloxacin as post-exposure therapy against inhalational anthrax in the common marmoset (Callithrix jacchus) with other non-human primate models in order to determine whether the marmoset is a suitable model to test post-exposure therapies for anthrax." | 3.77 | Post-exposure therapy of inhalational anthrax in the common marmoset. ( Brown, MA; Lever, MS; Nelson, M; Pearce, PC; Simpson, AJ; Stagg, AJ; Stevens, DJ, 2011) |
| " The current standard of care for inhalational anthrax postexposure prophylaxis is ciprofloxacin therapy twice daily for 60 days." | 3.74 | Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. ( Arhin, FF; Bassett, A; Bassett, J; Heine, HS; Ivins, BE; Lehoux, D; Miller, L; Moeck, G; Parr, TR, 2008) |
| "Long-term amoxicillin, ciprofloxacin, and doxycycline appear safe, supporting use of these medications if needed for large-scale post-exposure anthrax prophylaxis." | 3.74 | Adverse events associated with prolonged antibiotic use. ( Chan, KA; Chen, Z; Finkelstein, JA; Hennessy, S; Lautenbach, E; Meropol, SB; Metlay, JP; Platt, R; Schech, SD; Shatin, D, 2008) |
| " This study investigated the survival of non-irradiated and (60)Co-gamma-irradiated mice given therapy for inhalation anthrax with ciprofloxacin (CIP) or a clinically relevant mixture of clarithromycin (CLR) and its major human microbiologically important metabolite 14-hydroxy clarithromycin (14-OH CLR)." | 3.73 | Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without (60)Co gamma-photon irradiation. ( Brook, I; Elliott, TB; Germana, A; Giraldo, DE; Jackson, WE; Ledney, GD; Nicolau, DP; Shoemaker, MO; Thakar, JH, 2005) |
| "To compare the fluoroquinolones gatifloxacin and moxifloxacin with ciprofloxacin for post-exposure prophylaxis of systemic anthrax in a BALB/c mouse model." | 3.72 | Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. ( Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J, 2004) |
| "Ciprofloxacin or doxycycline is recommended for antimicrobial prophylaxis and treatment of adults and children with Bacillus anthracis infection associated with the recent bioterrorist attacks in the United States." | 3.71 | Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. ( , 2001) |
| "Comparative antibacterial activity and protective efficacy of ciprofloxacin, pefloxacin and lomefloxacin were estimated in a model of anthrax." | 3.69 | [Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection]. ( D'iakov, SI; Katsalukha, VV; Lebedeva, IK; Lukashina, AV; Raĭskaia, VA, 1994) |
| "Anthrax is endemic to many countries, including the United States." | 2.82 | Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019. ( Bower, WA; Bulitta, JB; Chatham-Stephens, K; Cook, R; Hendricks, K; Kennedy, JL; Mongkolrattanothai, T; Negron, ME; Person, MK; Shin, E; Yu, P, 2022) |
| "While cutaneous anthrax is most common, its early stages are distinct and prompt appropriate treatment commonly produces a good outcome." | 2.48 | An overview of anthrax infection including the recently identified form of disease in injection drug users. ( Cui, X; Eichacker, PQ; Hicks, CW; Li, Y; Sweeney, DA, 2012) |
| "Anthrax is still an endemic disease in some countries in the world and has become a re-emerging disease in western countries with recent intentional outbreak." | 2.46 | A review of cutaneous anthrax and its outcome. ( Alp, E; Doganay, M; Metan, G, 2010) |
| "Ciprofloxacin has a pediatric indication only when a child is potentially exposed to inhaled anthrax." | 2.41 | Anthrax: safe treatment for children. ( Benavides, S; Nahata, MC, 2002) |
| "Anthrax is a zoonotic disease caused by Bacillus anthracis." | 2.40 | [Pulmonary anthrax]. ( Debord, T; Vidal, D, 1998) |
| " Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens." | 1.56 | Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines. ( Barnewall, RE; Ionin, B; Lemiale, L; Park, S; Perry, MR; Reece, JJ; Savransky, V; Shearer, JD; Skiadopoulos, MH; Vassar, ML, 2020) |
| "Treatment of anthrax is challenging, especially during the advanced stages of the disease." | 1.48 | Treating Anthrax-Induced Meningitis in Rabbits. ( Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2018) |
| "Anthrax is a zoonotic occupational disease caused by Bacillus anthracis, a rod-shaped immobile aerobic gram-positive bacteria with spore." | 1.43 | A case report of inhalation anthrax acquired naturally. ( Azarkar, Z; Bidaki, MZ, 2016) |
| "Anthrax is still a serious public health problem in Turkey." | 1.43 | Cutaneous anthrax: evaluation of 28 cases in the Eastern Anatolian region of Turkey. ( Akbulut, A; Demir, B; Denk, A; Ozden, M; Tartar, AS, 2016) |
| "Respiratory anthrax is a fatal disease in the absence of early treatment with antibiotics." | 1.42 | Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits. ( Altboum, Z; Bar-David, E; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S, 2015) |
| "Cutaneous anthrax is an infection of the skin caused by Bacillus anthracis." | 1.40 | Cutaneous anthrax in a school teacher. ( Alam, MA; Baidya, NR; Kamal, MM; Mostafa, SM; Nandi, AK; Rahman, F; Uddin, MJ, 2014) |
| "Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection in humans, manifesting in different initial presentations of disease." | 1.40 | Pediatric anthrax clinical management. ( Bower, WA; Bradley, JS; Cohn, AC; Krug, SE; Meaney-Delman, D; Pavia, AT; Peacock, G, 2014) |
| "Anthrax is occasionally encountered by U." | 1.39 | Field-based PCR for rapid diagnosis of cutaneous anthrax in the deployed setting using the joint biological agent identification and diagnostic system. ( Krivda, S; Norton, SA; Pace, S; Steigelman, D, 2013) |
| "Anthrax is a rare disease caused by Bacillus anthracis." | 1.39 | Evaluation of cutaneous palpebral anthrax. ( Ari, S; Dal, T; Dayan, S; Dursun, B; Kaya, S; Kortak, MZ; Tekin, R, 2013) |
| "Anthrax was suspected primarily based on cutaneous manifestations of typical non-tender ulcer with black eschar, with or without oedema, and a history of butchering, or dressing/washing of cattle/goat or their meat." | 1.38 | Recent outbreak of cutaneous anthrax in Bangladesh: clinico-demographic profile and treatment outcome of cases attended at Rajshahi Medical College Hospital. ( Ahmed, SS; Akhtaruzzaman, SM; Anwar, KS; Khan, MA; Salam, MA; Siddiqui, MA, 2012) |
| " The effect of simulated clinical regimens of ciprofloxacin and linezolid on the vegetative and spore populations and on toxin production was examined in an in vitro pharmacodynamic model over 15 days by using the toxin-producing Sterne strain of B." | 1.38 | Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. ( Abshire, T; Brown, DL; Drusano, GL; Heine, HS; Holman, K; Kulawy, R; Liu, W; Louie, A; Vanscoy, BD, 2012) |
| " The sigmoid maximum-threshold-of-efficacy (E(max)) model fit the survival data, in which the free-drug area under the concentration-time curve (fAUC)/MIC ratio, the maximum concentration of free drug in plasma (fC(max))/MIC ratio, and the cumulative percentage of a 24-h period that the free-drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (f %T(MIC)) were each evaluated." | 1.36 | Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model. ( Ambrose, PG; Bassett, J; Beaudry, A; Bhavnani, SM; Critchley, I; Gill, SC; Heine, HS; Janjic, N; Li, J; Miller, L; Rubino, CM; Stone, KC, 2010) |
| " The lower dosage for the pharmacodynamically optimized regimen may decrease drug toxicity." | 1.35 | Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. ( Brown, DL; Drusano, GL; Heine, HS; Kim, K; Kinzig-Schippers, M; Liu, W; Louie, A; Sörgel, F; VanScoy, B, 2008) |
| "Incidence of anthrax is diminishing in developed countries; however, it remains a public health problem in developing countries, especially those whose main source of income is farming." | 1.35 | Characteristics of cutaneous anthrax in Turkey. ( Baykam, N; Celikbas, A; Dokuzoguz, B; Eren, S; Ergonul, O; Eroglu, M; Ulu, A, 2009) |
| "If left untreated, cutaneous anthrax may progress in 5 to 20% of cases to septicaemia with potentially lethal central nervous system involvement." | 1.35 | [Cutaneous anthrax: seven cases]. ( Alifadl, A; Azouzi, AI; Bjani, L; Chraibi, H; Gaamouche, K; Haouach, K; Kaidi, A; Khalidi, TE; Mountasser, A, 2009) |
| "Participants were monitored for adverse events (AEs)." | 1.33 | An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. ( Apicella, L; Aranas, A; Franzke, LH; Marano, N; Martin, SW; McNeil, MM; Rosenstein, NE; Tierney, BC, 2005) |
| "Inhalation anthrax is characterized by a systemic spread of the challenge agent, Bacillus anthracis." | 1.33 | Effective antiprotease-antibiotic treatment of experimental anthrax. ( Alibek, K; Bailey, C; Chandhoke, V; Fryxell, KJ; Hopkins, S; MacAfee, R; Popov, SG; Popova, TG; Weinstein, RS, 2005) |
| "Although cutaneous anthrax is usually self-limiting, complications may arise in untreated cases." | 1.33 | An unusually extensive case of cutaneous anthrax in a patient with type II diabetes mellitus. ( Ayaslioglu, E; Beygo, B; Erkek, E; Ozluk, U, 2005) |
| " We sought to determine whether a short course of antibiotic prophylaxis after exposure could protect non-human primates from a high-dose spore challenge if vaccination was combined with antibiotics." | 1.33 | Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. ( Friedlander, AM; Gamble, CS; Heine, HS; Ivins, BE; Lawler, JV; Leffel, EK; Purcell, BK; Rico, P; Sheeler, R; Twenhafel, NA; Vietri, NJ; Wright, ME, 2006) |
| "Moxifloxacin was just as effective as clindamycin." | 1.33 | Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice. ( Bolduc, DL; Brook, I; Camp-Hyde, TD; Elliott, TB; Foriska, MA; Germana, A; Giraldo, DE; Jackson, WE; Ledney, GD; Shoemaker, MO; Thakar, JH, 2005) |
| "During influenza season, our findings support rapid testing for influenza, followed by empiric treatment for anthrax pending blood culture results for those who test negative for influenza." | 1.32 | Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. ( Fine, AM; Fleisher, GR; Fraser, HS; Mandl, KD; Wong, JB, 2004) |
| "Guidelines for prophylactic treatment of anthrax and treatment of suspected active cases of anthrax are changing continually, and the Centers for Disease Control and Prevention web site should be consulted for the latest recommendations." | 1.31 | Management of asymptomatic pregnant or lactating women exposed to anthrax. ( , 2002) |
| " Adverse events associated with antimicrobial prophylaxis to prevent anthrax were commonly reported, but hospitalizations and serious adverse events as defined by Food and Drug Administration criteria were rare." | 1.31 | Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. ( Factor, S; Goldstein, S; Hayslett, J; Jones, J; Lukacs, S; Ridzon, R; Rosenstein, N; Shepard, CW; Soriano-Gabarro, M; Williams, I; Zell, ER, 2002) |
| "Pencillins are not recommended for treatment of anthrax, where such penicillinase activity may decrease their effectiveness." | 1.31 | Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis. ( , 2001) |
| " This report updates the investigation of these cases and describes adverse events associated with antimicrobial prophylaxis." | 1.31 | Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. ( , 2001) |
| " During October 26-November 6, 2001, an epidemiologic evaluation to detect adverse events associated with antimicrobial prophylaxis was conducted among 8,424 postal employees who had been offered antimicrobial prophylaxis for 60 days in New Jersey (NJ), New York City (NYC), and one postal facility in the District of Columbia (DC)." | 1.31 | Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001. ( , 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.41) | 18.2507 |
| 2000's | 109 (76.76) | 29.6817 |
| 2010's | 26 (18.31) | 24.3611 |
| 2020's | 5 (3.52) | 2.80 |
| Authors | Studies |
|---|---|
| Heine, HS | 8 |
| Bassett, J | 4 |
| Miller, L | 4 |
| Hartings, JM | 1 |
| Ivins, BE | 4 |
| Pitt, ML | 1 |
| Fritz, D | 1 |
| Norris, SL | 1 |
| Byrne, WR | 2 |
| Shiryaev, SA | 1 |
| Remacle, AG | 1 |
| Ratnikov, BI | 1 |
| Nelson, NA | 1 |
| Savinov, AY | 1 |
| Wei, G | 1 |
| Bottini, M | 1 |
| Rega, MF | 1 |
| Parent, A | 1 |
| Desjardins, R | 1 |
| Fugere, M | 1 |
| Day, R | 1 |
| Sabet, M | 1 |
| Pellecchia, M | 1 |
| Liddington, RC | 1 |
| Smith, JW | 1 |
| Mustelin, T | 1 |
| Guiney, DG | 1 |
| Lebl, M | 1 |
| Strongin, AY | 1 |
| Maples, KR | 1 |
| Wheeler, C | 1 |
| Ip, E | 1 |
| Plattner, JJ | 1 |
| Chu, D | 1 |
| Zhang, YK | 1 |
| Preobrazhenskaya, MN | 1 |
| Printsevskaya, SS | 1 |
| Solovieva, SE | 1 |
| Olsufyeva, EN | 1 |
| Heine, H | 1 |
| Lovchik, J | 1 |
| Lyons, CR | 1 |
| Louie, A | 3 |
| Kim, K | 1 |
| Brown, DL | 3 |
| VanScoy, B | 1 |
| Liu, W | 2 |
| Kinzig-Schippers, M | 1 |
| Sörgel, F | 2 |
| Drusano, GL | 3 |
| Bassett, A | 1 |
| Lehoux, D | 1 |
| Arhin, FF | 1 |
| Parr, TR | 1 |
| Moeck, G | 1 |
| Okusanya, OO | 1 |
| Okusanya, A | 1 |
| Van Scoy, B | 1 |
| Kulawy, R | 2 |
| Gill, SC | 1 |
| Rubino, CM | 1 |
| Ambrose, PG | 1 |
| Bhavnani, SM | 1 |
| Beaudry, A | 1 |
| Li, J | 1 |
| Stone, KC | 1 |
| Critchley, I | 1 |
| Janjic, N | 1 |
| Purcell, BK | 3 |
| Kennedy, JL | 1 |
| Bulitta, JB | 1 |
| Chatham-Stephens, K | 1 |
| Person, MK | 1 |
| Cook, R | 1 |
| Mongkolrattanothai, T | 1 |
| Shin, E | 1 |
| Yu, P | 1 |
| Negron, ME | 1 |
| Bower, WA | 2 |
| Hendricks, K | 2 |
| McCurdy, S | 1 |
| Halasohoris, SA | 1 |
| Babyak, AL | 1 |
| Lembirik, S | 1 |
| Hoover, R | 1 |
| Hickman, M | 1 |
| Scarff, J | 1 |
| Klimko, CP | 2 |
| Cote, CK | 2 |
| Meinig, JM | 1 |
| Stratilo, CW | 1 |
| Jager, S | 1 |
| Crichton, M | 1 |
| Blanchard, JD | 1 |
| Perry, MR | 1 |
| Ionin, B | 1 |
| Barnewall, RE | 1 |
| Vassar, ML | 1 |
| Reece, JJ | 1 |
| Park, S | 1 |
| Lemiale, L | 1 |
| Skiadopoulos, MH | 1 |
| Shearer, JD | 1 |
| Savransky, V | 1 |
| Kibar Ozturk, M | 1 |
| Vietri, NJ | 3 |
| Tobery, SA | 2 |
| Chabot, DJ | 1 |
| Ingavale, S | 1 |
| Somerville, BC | 1 |
| Miller, JA | 1 |
| Schellhase, CW | 1 |
| Twenhafel, NA | 3 |
| Fetterer, DP | 1 |
| Boyer, AE | 1 |
| Woolfitt, AR | 1 |
| Barr, JR | 1 |
| Wright, ME | 3 |
| Friedlander, AM | 4 |
| Alumasa, JN | 1 |
| Goralski, TDP | 1 |
| Keiler, KC | 1 |
| Ben-Shmuel, A | 1 |
| Glinert, I | 2 |
| Sittner, A | 2 |
| Bar-David, E | 2 |
| Schlomovitz, J | 2 |
| Brosh, T | 1 |
| Kobiler, D | 3 |
| Weiss, S | 2 |
| Levy, H | 2 |
| Tekin, R | 1 |
| Ari, S | 1 |
| Dal, T | 1 |
| Kaya, S | 1 |
| Kortak, MZ | 1 |
| Dursun, B | 1 |
| Dayan, S | 1 |
| Pace, S | 1 |
| Steigelman, D | 1 |
| Norton, SA | 1 |
| Krivda, S | 1 |
| Turhanoğlu, NM | 1 |
| Bayındır Bilman, F | 1 |
| Kutlu Yürüker, S | 1 |
| Veraldi, S | 1 |
| Nazzaro, G | 1 |
| Çuka, E | 1 |
| Drago, L | 1 |
| Chatterjee, K | 1 |
| Chaudhuri, A | 1 |
| Chatterjee, G | 1 |
| Parlak, E | 2 |
| Parlak, M | 2 |
| Atli, SB | 1 |
| Bradley, JS | 1 |
| Peacock, G | 1 |
| Krug, SE | 1 |
| Cohn, AC | 1 |
| Meaney-Delman, D | 1 |
| Pavia, AT | 1 |
| Nandi, AK | 1 |
| Kamal, MM | 1 |
| Alam, MA | 1 |
| Rahman, F | 1 |
| Uddin, MJ | 1 |
| Baidya, NR | 1 |
| Mostafa, SM | 1 |
| Denk, A | 1 |
| Tartar, AS | 1 |
| Ozden, M | 1 |
| Demir, B | 1 |
| Akbulut, A | 1 |
| Altboum, Z | 2 |
| Azarkar, Z | 1 |
| Bidaki, MZ | 1 |
| Allen, KC | 1 |
| Sergienko, E | 1 |
| Mirza, R | 1 |
| Chitale, RA | 1 |
| Rasmussen, SL | 1 |
| Leffel, EK | 2 |
| Kellogg, MD | 1 |
| Webster, WM | 1 |
| Chraibi, H | 1 |
| Haouach, K | 1 |
| Azouzi, AI | 1 |
| Gaamouche, K | 1 |
| Kaidi, A | 1 |
| Khalidi, TE | 1 |
| Alifadl, A | 1 |
| Bjani, L | 1 |
| Mountasser, A | 1 |
| Migone, TS | 1 |
| Subramanian, GM | 1 |
| Zhong, J | 1 |
| Healey, LM | 1 |
| Corey, A | 1 |
| Devalaraja, M | 1 |
| Lo, L | 1 |
| Ullrich, S | 1 |
| Zimmerman, J | 1 |
| Chen, A | 1 |
| Lewis, M | 1 |
| Meister, G | 1 |
| Gillum, K | 1 |
| Sanford, D | 1 |
| Mott, J | 1 |
| Bolmer, SD | 1 |
| Thomas, JM | 1 |
| Moen, ST | 1 |
| Gnade, BT | 1 |
| Vargas-Inchaustegui, DA | 1 |
| Foltz, SM | 1 |
| Suarez, G | 1 |
| Heidner, HW | 1 |
| König, R | 1 |
| Chopra, AK | 2 |
| Peterson, JW | 2 |
| Baykam, N | 1 |
| Ergonul, O | 1 |
| Ulu, A | 1 |
| Eren, S | 1 |
| Celikbas, A | 1 |
| Eroglu, M | 1 |
| Dokuzoguz, B | 1 |
| Doganay, M | 3 |
| Metan, G | 2 |
| Alp, E | 1 |
| Nelson, M | 1 |
| Stagg, AJ | 1 |
| Stevens, DJ | 1 |
| Brown, MA | 1 |
| Pearce, PC | 1 |
| Simpson, AJ | 3 |
| Lever, MS | 2 |
| Duncan, KO | 1 |
| Smith, TL | 1 |
| Vanscoy, BD | 1 |
| Abshire, T | 1 |
| Holman, K | 1 |
| Veach, RA | 1 |
| Zienkiewicz, J | 1 |
| Collins, RD | 1 |
| Hawiger, J | 1 |
| Kayabas, U | 1 |
| Karahocagil, MK | 1 |
| Ozkurt, Z | 1 |
| Bayindir, Y | 1 |
| Kalkan, A | 1 |
| Akdeniz, H | 1 |
| Hicks, CW | 1 |
| Sweeney, DA | 1 |
| Cui, X | 1 |
| Li, Y | 1 |
| Eichacker, PQ | 1 |
| Siddiqui, MA | 1 |
| Khan, MA | 1 |
| Ahmed, SS | 1 |
| Anwar, KS | 1 |
| Akhtaruzzaman, SM | 1 |
| Salam, MA | 1 |
| Panchal, RG | 1 |
| Geller, BL | 1 |
| Mellbye, B | 1 |
| Lane, D | 1 |
| Iversen, PL | 1 |
| Bavari, S | 1 |
| Atlas, RM | 1 |
| Austin, PC | 1 |
| Mamdani, MM | 1 |
| Jaakkimainen, L | 1 |
| Hux, JE | 1 |
| Lothstein, LM | 1 |
| Chakrabarty, AM | 1 |
| Resnik, DB | 1 |
| DeVille, KA | 1 |
| Kaye, KS | 1 |
| Kaye, D | 1 |
| Dresser, R | 1 |
| Trachtman, H | 1 |
| Greenfield, RA | 1 |
| Drevets, DA | 1 |
| Gilmore, MS | 1 |
| Torres-Tortosa, M | 1 |
| Caballero-Granado, FJ | 1 |
| Moreno, I | 1 |
| Canueto, J | 1 |
| Gozes, Y | 1 |
| Barnea, A | 1 |
| Pass, A | 1 |
| White, M | 1 |
| Levenson, D | 1 |
| Williams, JL | 1 |
| Noviello, SS | 1 |
| Griffith, KS | 1 |
| Wurtzel, H | 1 |
| Hamborsky, J | 1 |
| Perz, JF | 1 |
| Williams, IT | 1 |
| Hadler, JL | 1 |
| Swerdlow, DL | 1 |
| Ridzon, R | 2 |
| Shepard, CW | 1 |
| Soriano-Gabarro, M | 1 |
| Zell, ER | 1 |
| Hayslett, J | 1 |
| Lukacs, S | 1 |
| Goldstein, S | 1 |
| Factor, S | 1 |
| Jones, J | 1 |
| Williams, I | 1 |
| Rosenstein, N | 1 |
| Chen, M | 1 |
| Bonat, J | 1 |
| Swezey, R | 1 |
| Tsai, AC | 1 |
| Lurie, P | 1 |
| Sehgal, AR | 1 |
| Levine, SM | 1 |
| Perez-Perez, G | 1 |
| Olivares, A | 1 |
| Yee, H | 1 |
| Hanna, BA | 1 |
| Blaser, MJ | 1 |
| Coleman, EA | 1 |
| Bossi, P | 1 |
| Bricaire, F | 1 |
| Meyer, MA | 1 |
| Kawana, R | 1 |
| Holtz, TH | 1 |
| Ackelsberg, J | 1 |
| Kool, JL | 1 |
| Rosselli, R | 1 |
| Marfin, A | 1 |
| Matte, T | 1 |
| Beatrice, ST | 1 |
| Heller, MB | 1 |
| Hewett, D | 1 |
| Moskin, LC | 1 |
| Bunning, ML | 1 |
| Layton, M | 1 |
| Esel, D | 1 |
| Sumerkan, B | 1 |
| Martin, G | 1 |
| Jones, ME | 1 |
| Goguen, J | 1 |
| Critchley, IA | 1 |
| Draghi, DC | 1 |
| Karlowsky, JA | 1 |
| Sahm, DF | 1 |
| Porschen, R | 1 |
| Patra, G | 1 |
| DelVecchio, VG | 1 |
| Vanderford, ML | 1 |
| Karginov, VA | 1 |
| Robinson, TM | 1 |
| Riemenschneider, J | 1 |
| Golding, B | 1 |
| Kennedy, M | 1 |
| Shiloach, J | 1 |
| Alibek, K | 2 |
| Schultz, CH | 1 |
| Fine, AM | 1 |
| Wong, JB | 1 |
| Fraser, HS | 1 |
| Fleisher, GR | 1 |
| Mandl, KD | 1 |
| Steward, J | 1 |
| Sefton, AM | 1 |
| Brooks, TJ | 1 |
| Fama, U | 1 |
| Irace, S | 1 |
| Frati, R | 1 |
| de Gado, F | 1 |
| Scuderi, N | 1 |
| Meyerhoff, A | 1 |
| Albrecht, R | 1 |
| Meyer, JM | 1 |
| Dionne, P | 1 |
| Higgins, K | 1 |
| Murphy, D | 1 |
| Hupert, N | 1 |
| Chege, W | 1 |
| Bearman, GM | 1 |
| Pelzman, FN | 1 |
| M'ikanatha, NM | 1 |
| Julian, KG | 1 |
| Kunselman, AR | 1 |
| Aber, RC | 1 |
| Rankin, JT | 1 |
| Lautenbach, E | 2 |
| Fidler, DP | 1 |
| Martin, SW | 1 |
| Tierney, BC | 1 |
| Aranas, A | 1 |
| Rosenstein, NE | 1 |
| Franzke, LH | 1 |
| Apicella, L | 1 |
| Marano, N | 1 |
| McNeil, MM | 1 |
| Popov, SG | 1 |
| Popova, TG | 1 |
| Hopkins, S | 1 |
| Weinstein, RS | 1 |
| MacAfee, R | 1 |
| Fryxell, KJ | 1 |
| Chandhoke, V | 1 |
| Bailey, C | 1 |
| Godyn, JJ | 1 |
| Reyes, L | 1 |
| Siderits, R | 1 |
| Hazra, A | 1 |
| Shoop, WL | 1 |
| Xiong, Y | 1 |
| Wiltsie, J | 1 |
| Woods, A | 1 |
| Guo, J | 1 |
| Pivnichny, JV | 1 |
| Felcetto, T | 1 |
| Michael, BF | 1 |
| Bansal, A | 1 |
| Cummings, RT | 1 |
| Cunningham, BR | 1 |
| Douglas, CM | 1 |
| Patel, SB | 1 |
| Wisniewski, D | 1 |
| Scapin, G | 1 |
| Salowe, SP | 1 |
| Zaller, DM | 1 |
| Chapman, KT | 1 |
| Scolnick, EM | 1 |
| Schmatz, DM | 1 |
| Bartizal, K | 1 |
| MacCoss, M | 1 |
| Hermes, JD | 1 |
| Bork, KH | 1 |
| Heegaard, ED | 1 |
| Nielsen, J | 1 |
| Kogutowska, E | 1 |
| Heegaard, NH | 1 |
| Erkek, E | 1 |
| Ayaslioglu, E | 1 |
| Beygo, B | 1 |
| Ozluk, U | 1 |
| Brook, I | 2 |
| Germana, A | 2 |
| Giraldo, DE | 2 |
| Camp-Hyde, TD | 1 |
| Bolduc, DL | 1 |
| Foriska, MA | 1 |
| Elliott, TB | 2 |
| Thakar, JH | 2 |
| Shoemaker, MO | 2 |
| Jackson, WE | 2 |
| Ledney, GD | 2 |
| Nicolau, DP | 1 |
| Barrow, EW | 1 |
| Valderas, MW | 1 |
| Bourne, PC | 1 |
| Barrow, WW | 1 |
| Comer, JE | 1 |
| Noffsinger, DM | 1 |
| Wenglikowski, A | 1 |
| Walberg, KG | 1 |
| Chatuev, BM | 1 |
| Stanberry, LR | 1 |
| Kang, AS | 1 |
| Scholz, WW | 1 |
| Sircar, J | 1 |
| Lawler, JV | 1 |
| Rico, P | 1 |
| Gamble, CS | 1 |
| Sheeler, R | 1 |
| Yetkin, MA | 1 |
| Erdinc, FS | 1 |
| Bulut, C | 1 |
| Tulek, N | 1 |
| Bindu, M | 1 |
| Vengamma, B | 1 |
| Kumar, G | 1 |
| Meropol, SB | 1 |
| Chan, KA | 1 |
| Chen, Z | 1 |
| Finkelstein, JA | 1 |
| Hennessy, S | 1 |
| Platt, R | 1 |
| Schech, SD | 1 |
| Shatin, D | 1 |
| Metlay, JP | 1 |
| D'iakov, SI | 1 |
| Katsalukha, VV | 1 |
| Lebedeva, IK | 1 |
| Lukashina, AV | 1 |
| Raĭskaia, VA | 1 |
| Debord, T | 1 |
| Vidal, D | 1 |
| Josefson, D | 1 |
| Eaton, L | 1 |
| Charatan, F | 2 |
| Enserink, M | 1 |
| Cowley, G | 1 |
| Lemonick, MD | 1 |
| Comarow, A | 2 |
| Kinsley, M | 1 |
| SoRelle, R | 1 |
| Gallagher, TC | 1 |
| Strober, BE | 1 |
| Shute, N | 1 |
| Spake, A | 1 |
| Mayer, TA | 1 |
| Bersoff-Matcha, S | 1 |
| Murphy, C | 1 |
| Earls, J | 1 |
| Harper, S | 1 |
| Pauze, D | 1 |
| Nguyen, M | 1 |
| Rosenthal, J | 1 |
| Cerva, D | 1 |
| Druckenbrod, G | 1 |
| Hanfling, D | 1 |
| Fatteh, N | 1 |
| Napoli, A | 1 |
| Nayyar, A | 1 |
| Berman, EL | 1 |
| Brown, K | 1 |
| Petsko, GA | 1 |
| Diamond, F | 1 |
| Smith, SG | 1 |
| Farber, MS | 1 |
| Howarth, GR | 1 |
| Altman, LK | 1 |
| Abeleson, R | 1 |
| Pollack, A | 1 |
| Regan, LE | 1 |
| Robinson-Bostom, L | 1 |
| Weinstock, MA | 1 |
| Brower, V | 1 |
| Persell, DJ | 1 |
| Arangie, P | 1 |
| Young, C | 1 |
| Stokes, EN | 1 |
| Payne, WC | 1 |
| Skorga, P | 1 |
| Gilbert-Palmer, D | 1 |
| Wirtschafter, A | 1 |
| Cherukuri, S | 1 |
| Benninger, MS | 1 |
| Tutrone, WD | 1 |
| Scheinfeld, NS | 1 |
| Weinberg, JM | 1 |
| Gorman, C | 1 |
| Benavides, S | 1 |
| Nahata, MC | 1 |
| Bodasing, N | 1 |
| Seaton, RA | 1 |
| Bell, DM | 1 |
| Kozarsky, PE | 1 |
| Stephens, DS | 1 |
| Celia, F | 1 |
| Wood, L | 1 |
| Makino, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects[NCT00639678] | Phase 3 | 322 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients[NCT00050310] | 200 participants (Anticipated) | Observational | 2002-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants who developed an anti-raxibacumab antibody response during the study were assessed. .Immunogenicity testing was performed to determine if raxibacumab induced an anti-raxibacumab immune response. Testing comprised of 2 assays (screening and confirmatory). The screening assay (direct binding) was an electrochemiluminescence (ECL)-based bridging assay. A rabbit polyclonal antibody was used as a positive control. Samples above the assay cut point were considered positive. Samples identified as positive in the screening assay were confirmed positive in a confirmatory assay. Samples must have demonstrated a significant percent drop in the confirmatory inhibition of binding assay to be considered positive. The inhibition of binding confirmatory assay was performed identically to the direct binding screening assay with the exception that the samples were tested in parallel with excess unlabeled raxibacumab. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Clinical thyroid parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) |
|---|---|
| Placebo - Single-Dose | 0 |
| Placebo - Double-Dose | 0 |
| Raxibacumab - Single-Dose | 0 |
| Raxibacumab - Double-Dose | 0 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. Blood samples for serum raxibacumab concentration measurement were collected from participants who received a single-dose prior to administration of the raxibacumab and diphenhydramine doses on Day 0, at 30 minutes and 2 to 6 hours after completion of the raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Day 0, at 30 minutes and 2 to 6 hours after completion of raxibacumab infusion, and at 14, 28, and 56 days after the raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Predose | 30 minutes post-dose | 2-6 hours post-dose | Day 14 | Day 28 | Day 56 | |
| Raxibacumab - Single-Dose | 0.048 | 928.447 | 881.586 | 311.669 | 199.043 | 89.021 |
Blood was collected from each participant at selected times post dose, and serum specimens were analyzed for raxibacumab using a validated electrochemiluminescense-based assay. The individual serum raxibacumab concentration data were summarized by nominal collection time and treatment group using descriptive statistics. For the participants that received two doses, blood samples for serum raxibacumab concentration measurement were collected from participants prior to administration of the raxibacumab and diphenhydramine doses on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose. (NCT00639678)
Timeframe: Pre-dose on Days 0 and 14, at 30 minutes and 2 to 6 hours after completion of each raxibacumab infusion, and at 28, 42, 56, and 70 days after the 1st raxibacumab dose
| Intervention | Micrograms per milliliter (μg/mL) (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose 1 - Predose | Dose 1 - 30 minutes post-dose | Dose 1 - 2-6 hours post-dose | Dose 2 - Predose | Dose 2 - 30 minutes post-dose | Dose 2 - 2-6 hours post-dose | Dose 2 - Day 14 | Dose 2 - Day 28 | Dose 2 - Day 42 | Dose 2 - Day 56 | |
| Raxibacumab - Double-Dose | 0 | 1012.564 | 973.910 | 314.374 | 1246.223 | 1211.572 | 543.767 | 334.431 | 213.463 | 137.878 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. This includes worsening (eg, increase in frequency or severity) of pre-existing conditions. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Any AE | Any SAE | |
| Placebo - Double-Dose | 6 | 1 |
| Placebo - Single-Dose | 32 | 0 |
| Raxibacumab - Double-Dose | 10 | 1 |
| Raxibacumab - Single-Dose | 103 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in electrolyte toxicities were assessed. Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, any >=2-grade worsening | Hyponatremia, any >=2-grade worsening | Hyperkalemia, any >=2-grade worsening | Hypokalemia, any >=2-grade worsening | Hypomagnesemia, any >=2-grade worsening | HrC/adjusted for albumin, any >=2-grade worsening | HoC/adjusted for albumin, any >=2-grade worsening | Hypercalcemia/unadjusted, any >=2-grade worsening | Hypocalcemia/unadjusted, any >=2-grade worsening | Hypophosphatemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 5 |
The number of participants with at least a 2-grade worsening from Baseline in hematological toxicities were assessed. Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Leukocytosis, any >=2-grade worsening | Leukopenia, any >=2-grade worsening | Neutropenia, any >=2-grade worsening | Lymphopenia, any >=2-grade worsening | Hemoglobin, any >=2-grade worsening | Platelet, any >=2-grade worsening | Prothrombin Time, any >=2-grade worsening | Activated PTT, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 1 | 2 | 1 | 0 | 0 | 2 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in liver toxicities were assessed. Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AST, any >=2-grade worsening | ALT, any >=2-grade worsening | GGT, any >=2-grade worsening | ALP, any >=2-grade worsening | Hyperbilirubinemia, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 1 | 0 | 0 | 0 |
The number of participants with at least a 2-grade worsening from Baseline in other chemistry toxicities were assessed. Other clinical chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Creatinine, any >=2-grade worsening | BUN, any >=2-grade worsening | Hypoalbuminemia, any >=2-grade worsening | Hyperuricemia, any >=2-grade worsening | Hyperglycemia, any >=2-grade worsening | Hypoglycemia, any >=2-grade worsening | Amylase, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
Urinalysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. Baseline is defined as the value of the variable measured at Day 0 prior to dosing. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |
|---|---|---|
| Proteinuria, any >=2-grade worsening | Hematuria, any >=2-grade worsening | |
| Placebo - Double-Dose | 0 | 0 |
| Placebo - Single-Dose | 3 | 4 |
| Raxibacumab - Double-Dose | 0 | 2 |
| Raxibacumab - Single-Dose | 8 | 12 |
Electrolyte function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hypernatremia, Grade 1 | Hypernatremia, Grade 2 | Hypernatremia, Grade 3 | Hypernatremia, Grade 4 | Hyponatremia, Grade 1 | Hyponatremia, Grade 2 | Hyponatremia, Grade 3 | Hyponatremia, Grade 4 | Hyperkalemia, Grade 1 | Hyperkalemia, Grade 2 | Hyperkalemia, Grade 3 | Hyperkalemia, Grade 4 | Hypokalemia, Grade 1 | Hypokalemia, Grade 2 | Hypokalemia, Grade 3 | Hypokalemia, Grade 4 | Hypomagnesemia, Grade 1 | Hypomagnesemia, Grade 2 | Hypomagnesemia, Grade 3 | Hypomagnesemia, Grade 4 | Hypercalcemia (HrC)/ adjusted for albumin, Grade 1 | HrC/ adjusted for albumin, Grade 2 | HrC/ adjusted for albumin, Grade 3 | HrC/ adjusted for albumin, Grade 4 | Hypocalcemia (HoC)/ adjusted for albumin, Grade 1 | HoC adjusted for albumin, Grade 2 | HoC/ adjusted for albumin, Grade 3 | HoC/ adjusted for albumin, Grade 4 | Hypercalcemia/ unadjusted, Grade 1 | Hypercalcemia/ unadjusted, Grade 2 | Hypercalcemia/ unadjusted, Grade 3 | Hypercalcemia/ unadjusted, Grade 4 | Hypocalcemia/ unadjusted, Grade 1 | Hypocalcemia/ unadjusted, Grade 2 | Hypocalcemia/ unadjusted, Grade 3 | Hypocalcemia/ unadjusted, Grade 4 | Hypophosphatemia, Grade 1 | Hypophosphatemia, Grade 2 | Hypophosphatemia, Grade 3 | Hypophosphatemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 0 | 0 | 0 | 0 | 20 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 5 | 0 | 0 |
Clinical hematological parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukocytosis, Grade 1 | Leukocytosis, Grade 2 | Leukocytosis, Grade 3 | Leukocytosis, Grade 4 | Leukopenia, Grade 1 | Leukopenia, Grade 2 | Leukopenia, Grade 3 | Leukopenia, Grade 4 | Neutropenia, Grade 1 | Neutropenia, Grade 2 | Neutropenia, Grade 3 | Neutropenia, Grade 4 | Lymphopenia, Grade 1 | Lymphopenia, Grade 2 | Lymphopenia, Grade 3 | Lymphopenia, Grade 4 | Hemoglobin, Grade 1 | Hemoglobin, Grade 2 | Hemoglobin, Grade 3 | Hemoglobin, Grade 4 | Platelet, Grade 1 | Platelet, Grade 2 | Platelet, Grade 3 | Platelet, Grade 4 | Prothrombin Time, Grade 1 | Prothrombin Time, Grade 2 | Prothrombin Time, Grade 3 | Prothrombin Time, Grade 4 | Activated PartialThromboplastinTime(PTT) , Grade 1 | Activated PTT, Grade 2 | Activated PTT, Grade 3 | Activated PTT, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 4 | 1 | 1 | 0 | 9 | 1 | 0 | 0 | 4 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 2 | 2 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 15 | 2 | 1 | 0 | 25 | 6 | 0 | 0 | 8 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 10 | 0 | 0 | 0 |
Liver function parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspartate amino transferase (AST), Grade 1 | AST, Grade 2 | AST, Grade 3 | AST, Grade 4 | Alanine amino transferase(ALT), Grade 1 | ALT, Grade 2 | ALT, Grade 3 | ALT, Grade 4 | Gamma-glutamyl-transferase (GGT), Grade 1 | GGT, Grade 2 | GGT, Grade 3 | GGT, Grade 4 | Alkaline Phosphatase(ALP), Grade 1 | ALP, Grade 2 | ALP, Grade 3 | ALP, Grade 4 | Hyperbilirubinemia, Grade 1 | Hyperbilirubinemia, Grade 2 | Hyperbilirubinemia, Grade 3 | Hyperbilirubinemia, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Raxibacumab - Single-Dose | 7 | 0 | 0 | 0 | 6 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
Other chemistry parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine, Grade 1 | Creatinine, Grade 2 | Creatinine, Grade 3 | Creatinine, Grade 4 | Blood Urea Nitrogen (BUN), Grade 1 | BUN, Grade 2 | BUN, Grade 3 | BUN, Grade 4 | Hypoalbuminemia, Grade 1 | Hypoalbuminemia, Grade 2 | Hypoalbuminemia, Grade 3 | Hypoalbuminemia, Grade 4 | Hyperuricemia, Grade 1 | Hyperuricemia, Grade 2 | Hyperuricemia, Grade 3 | Hyperuricemia, Grade 4 | Hyperglycemia, Grade 1 | Hyperglycemia, Grade 2 | Hyperglycemia, Grade 3 | Hyperglycemia, Grade 4 | Hypoglycemia, Grade 1 | Hypoglycemia, Grade 2 | Hypoglycemia, Grade 3 | Hypoglycemia, Grade 4 | Amylase, Grade 1 | Amylase, Grade 2 | Amylase, Grade 3 | Amylase, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 15 | 1 | 0 | 0 | 5 | 2 | 0 | 0 | 5 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 2 | 0 | 0 | 2 | 3 | 0 | 0 | 2 | 1 | 0 | 0 |
| Raxibacumab - Single-Dose | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 8 | 1 | 0 | 0 | 36 | 1 | 0 | 0 | 11 | 2 | 0 | 0 | 25 | 5 | 1 | 0 |
Urinaysis parameters were assessed using the modified Division of Microbiology and Infectious Diseases (DMID) toxicity tables, version 2.0. Grade 1 (Mild): Transient or mild discomfort (< 48 hours); no medical intervention or therapy required. Grade 2 (Moderate): Mild to moderate limitation in activity, some assistance may be needed; no or minimal medical intervention or therapy required. Grade 3 (Severe): Marked limitation in activity, some assistance usually required; medical intervention or therapy required, hospitalizations possible. Grade 4 (Life-threatening): Extreme limitation in activity, significant assistance required; significant medical intervention or therapy required, hospitalization or hospice care probable. (NCT00639678)
Timeframe: From the day of the first dose of study agent (Day 0) until Day 56 (single-dose) or until Day 70 (double-dose)
| Intervention | Participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Proteinuria, Grade 1 | Proteinuria, Grade 2 | Proteinuria, Grade 3 | Proteinuria, Grade 4 | Hematuria, Grade 1 | Hematuria, Grade 2 | Hematuria, Grade 3 | Hematuria, Grade 4 | |
| Placebo - Double-Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Placebo - Single-Dose | 9 | 3 | 0 | 0 | 9 | 4 | 0 | 0 |
| Raxibacumab - Double-Dose | 3 | 0 | 0 | 0 | 3 | 2 | 0 | 0 |
| Raxibacumab - Single-Dose | 31 | 9 | 0 | 0 | 17 | 15 | 0 | 0 |
15 reviews available for ciprofloxacin and Anthrax
| Article | Year |
|---|---|
Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Anti-Infecti | 2022 |
A review of cutaneous anthrax and its outcome.
Topics: Adolescent; Adult; Amoxicillin; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; D | 2010 |
An overview of anthrax infection including the recently identified form of disease in injection drug users.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2012 |
Bioterriorism: from threat to reality.
Topics: Animals; Anthrax; Bacterial Infections; Bioterrorism; Botulism; Cattle; Ciprofloxacin; Humans; Plagu | 2002 |
[Anthrax in the era of biowarfare].
Topics: Adult; Amoxicillin; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Biological Warfare; Biote | 2003 |
Neurologic complications of anthrax: a review of the literature.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Central Nervous System Infections; Ciprofloxacin | 2003 |
[Anthrax].
Topics: Animals; Anthrax; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Diagnosis, Differential; Humans; | 2003 |
US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax.
Topics: Adult; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Child, Preschool; Ciprofloxacin; | 2004 |
Cutaneous anthrax: conservative or surgical treatment?
Topics: Anthrax; Anti-Bacterial Agents; Biopsy; Bioterrorism; Ciprofloxacin; Diagnosis, Differential; Doxycy | 2005 |
[Pulmonary anthrax].
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Doxycycline; Humans; Pneumonia | 1998 |
Preparing for bioterrorism: category A agents.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bioterrorism; Botulism; Ciprofloxacin; Humans | 2001 |
Cutaneous anthrax: a concise review.
Topics: Administration, Oral; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Doxycycl | 2002 |
Anthrax: safe treatment for children.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Centers for Disease Contr | 2002 |
Cutaneous anthrax: an overview.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Chil | 2002 |
[Anthrax].
Topics: Animals; Anthrax; Anthrax Vaccines; Bacillus anthracis; Ciprofloxacin; Diagnosis, Differential; Huma | 2002 |
2 trials available for ciprofloxacin and Anthrax
| Article | Year |
|---|---|
Raxibacumab for the treatment of inhalational anthrax.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anthrax; Anti-Infective Agents; Antibodies, Bac | 2009 |
Naturally occurring cutaneous anthrax: antibiotic treatment and outcome.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Fe | 2012 |
125 other studies available for ciprofloxacin and Anthrax
| Article | Year |
|---|---|
Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxi | 2007 |
Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens.
Topics: Amino Acid Motifs; Amino Acid Sequence; Animals; Anthrax; Binding Sites; Furin; Hemagglutinin Glycop | 2007 |
Novel semisynthetic derivative of antibiotic Eremomycin active against drug-resistant gram-positive pathogens including Bacillus anthracis.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Drug Resistance, Bacterial; Glycopeptid | 2007 |
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
Topics: Acetamides; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Dose-Response Relationship, Drug; Dr | 2008 |
Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax.
Topics: Administration, Inhalation; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Disease Mod | 2008 |
Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis?
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Colony Count, Microbial; Drug Adm | 2008 |
Pharmacokinetic-pharmacodynamic assessment of faropenem in a lethal murine Bacillus anthracis inhalation postexposure prophylaxis model.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; beta-Lactamases; beta-Lactams; Blood Pr | 2010 |
Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Daptomycin; Female; Mice | 2010 |
Efficacy of delafloxacin against the biothreat pathogen Bacillus anthracis.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Mice; Microbial Sensitiv | 2023 |
Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.
Topics: Administration, Intranasal; Animals; Anthrax; Bacillus anthracis; Ciprofloxacin; Disease Models, Ani | 2020 |
Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; Gu | 2020 |
Suspected cutaneous anthrax in rural areas.
Topics: Adolescent; Adult; Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Doxycycline; Female; Humans; Male; | 2019 |
Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; | 2021 |
Tetrazole-Based
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Benzamides; Cell Line; Ciprofloxacin; M | 2017 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Cip | 2018 |
Evaluation of cutaneous palpebral anthrax.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anthrax; Anti-Bacterial Agents; Bacillus ant | 2013 |
Field-based PCR for rapid diagnosis of cutaneous anthrax in the deployed setting using the joint biological agent identification and diagnostic system.
Topics: Adolescent; Afghan Campaign 2001-; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin | 2013 |
[Four cases of cutaneous anthrax in Diyarbakir, Turkey].
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Cattle; Ciprofloxacin; Diagnosis, Diffe | 2013 |
Anthrax of the lower lip.
Topics: Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Combined Modality Therapy; Diagnosis, Differential; H | 2013 |
Charbon: a classical presentation.
Topics: Adult; Agriculture; Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Hand Dermatoses; Humans; Male; Oc | 2014 |
Unusual cause of fatal anthrax meningitis.
Topics: Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Fatal Outcome; Female; Humans; Meningitis; Middle Age | 2015 |
Pediatric anthrax clinical management.
Topics: Adolescent; Anthrax; Anthrax Vaccines; Bacillus anthracis; Biological Warfare Agents; Centers for Di | 2014 |
Cutaneous anthrax in a school teacher.
Topics: Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Faculty; Humans; Male; Middle Aged; Skin Diseases, Ba | 2014 |
Cutaneous anthrax: evaluation of 28 cases in the Eastern Anatolian region of Turkey.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anthrax; Anti-Bacterial Agents; Bacillus anthracis | 2016 |
Efficacy of Single and Combined Antibiotic Treatments of Anthrax in Rabbits.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anthrax; Anti-Bacterial Agents; Bacillus ant | 2015 |
A case report of inhalation anthrax acquired naturally.
Topics: Aged; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Clindamycin; Fatal | 2016 |
Notes from the Field: Compliance with Postexposure Prophylaxis for Exposure to Bacillus anthracis Among U.S. Military Personnel - South Korea, May 2015.
Topics: Amoxicillin; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Co | 2017 |
A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics.
Topics: Administration, Inhalation; Aerosols; Animals; Anthrax; Anti-Bacterial Agents; Bioterrorism; Ciprofl | 2009 |
[Cutaneous anthrax: seven cases].
Topics: Adolescent; Adult; Animals; Anthrax; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Mid | 2009 |
Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Neutra | 2009 |
Characteristics of cutaneous anthrax in Turkey.
Topics: Anthrax; Anti-Infective Agents; Ciprofloxacin; Developing Countries; Drug Therapy, Combination; Fema | 2009 |
Post-exposure therapy of inhalational anthrax in the common marmoset.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Callithrix; Ciprofloxacin; Disease Mode | 2011 |
Primary cutaneous infection with Bacillus megaterium mimicking cutaneous anthrax.
Topics: Adult; Anthrax; Bacillus megaterium; Ciprofloxacin; Diagnosis, Differential; Female; Follow-Up Studi | 2011 |
Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.
Topics: Acetamides; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bacterial Load; Bacterial Toxins; Ci | 2012 |
Lethality in a murine model of pulmonary anthrax is reduced by combining nuclear transport modifier with antimicrobial therapy.
Topics: Active Transport, Cell Nucleus; Animals; Anthrax; Anti-Infective Agents; Cell-Penetrating Peptides; | 2012 |
Recent outbreak of cutaneous anthrax in Bangladesh: clinico-demographic profile and treatment outcome of cases attended at Rajshahi Medical College Hospital.
Topics: Adolescent; Adult; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bangladesh; Cattle; | 2012 |
Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis.
Topics: Amino Acid Sequence; Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Base Sequence; Cel | 2012 |
Management of asymptomatic pregnant or lactating women exposed to anthrax.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Bacillus anthracis; Bi | 2002 |
Trends in drug prescriptions among elderly residents of Ontario in the weeks after September 11, 2001.
Topics: Aged; Anthrax; Anti-Bacterial Agents; Antidepressive Agents; Bioterrorism; Ciprofloxacin; Drug Presc | 2002 |
Ciprofloxacin: a warning for clinicians.
Topics: Anthrax; Anti-Infective Agents; Ciprofloxacin; Humans | 2002 |
Compulsory licensure: the case of Cipro and beyond.
Topics: Anthrax; Bioterrorism; Ciprofloxacin; Drug Industry; Embryo Research; Federal Government; Humans; In | 2002 |
Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro.
Topics: Anthrax; Bioterrorism; Ciprofloxacin; Compensation and Redress; Drug Industry; Ethical Analysis; Eth | 2002 |
The Cipro patent and bioterrorism.
Topics: Anthrax; Bioterrorism; Ciprofloxacin; Drug Industry; Federal Government; Humans; Licensure; Patents | 2002 |
Beyond government intervention: drug companies and bioethics.
Topics: Anthrax; Bioethics; Ciprofloxacin; Clinical Trials as Topic; Conflict of Interest; Drug Industry; Et | 2002 |
Who are the guardians guarding?
Topics: Anthrax; Bioterrorism; Ciprofloxacin; Drug Industry; Ethical Analysis; Federal Government; Patents a | 2002 |
Anthrax.
Topics: Animals; Anthrax; Bacillus anthracis; Biological Warfare; Bioterrorism; Ciprofloxacin; Humans; Unite | 2002 |
Antimicrobial therapy for anthrax.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Ciprofloxac | 2002 |
Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.
Topics: Animals; Anthrax; Anthrax Vaccines; Bacillus anthracis; Ciprofloxacin; Female; Guinea Pigs; Microbia | 2002 |
CDC: be alert to symptoms associated with bioterrorism.
Topics: Anthrax; Bioterrorism; Centers for Disease Control and Prevention, U.S.; Ciprofloxacin; Cluster Anal | 2001 |
Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001.
Topics: Adolescent; Adult; Aged; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylax | 2002 |
Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anthrax; Anti-Bacterial Agents; Anti-Infect | 2002 |
Fielding pleas for Cipro.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Drug Prescriptions; Humans; Nurse Pract | 2001 |
An outbreak of web sites selling ciprofloxacin following an outbreak of anthrax by mail.
Topics: Anthrax; Anti-Infective Agents; Ciprofloxacin; Commerce; Disease Outbreaks; Humans; Internet; Postal | 2002 |
PCR-based detection of Bacillus anthracis in formalin-fixed tissue from a patient receiving ciprofloxacin.
Topics: Adult; Anthrax; Anti-Infective Agents; Bacillus anthracis; Biopsy; Ciprofloxacin; Fixatives; Formald | 2002 |
Emergency. Anthrax.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bioterrorism; | 2001 |
Isolated case of bioterrorism-related inhalational anthrax, New York City, 2001.
Topics: Anthrax; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Disease Outbreaks; DNA, Bacterial; Environ | 2003 |
Antimicrobial susceptibilities of 40 isolates of Bacillus anthracis isolated in Turkey.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Doxycycline; Drug Resistance, Bac | 2003 |
Anthrax: lessons learned from the U.S. Capitol experience.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2003 |
Antibiotic susceptibility of isolates of Bacillus anthracis, a bacterial pathogen with the potential to be used in biowarfare.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Humans; Microbial S | 2003 |
Communication lessons learned in the Emergency Operations Center during CDC's anthrax response: a commentary.
Topics: Anthrax; Bioterrorism; Centers for Disease Control and Prevention, U.S.; Ciprofloxacin; Communicatio | 2003 |
Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis.
Topics: Animals; Anthrax; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacillus anthra | 2004 |
Chinese curses, anthrax, and the risk of bioterrorism.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Decision Support Techniques; | 2004 |
Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Ciprofloxacin; Decision Support Techniques; | 2004 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; F | 2004 |
Is it a real risk to take ciprofloxacin?
Topics: Adult; Anthrax; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Musculoskeletal Diseases; Tendin | 2004 |
Antibiotics for anthrax: patient requests and physician prescribing practices during the 2001 New York City attacks.
Topics: Adult; Aged; Aged, 80 and over; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bioterrorism | 2004 |
Patients' request for and emergency physicians' prescription of antimicrobial prophylaxis for anthrax during the 2001 bioterrorism-related outbreak.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bioterrorism; Ciprofloxacin; Doxycycline; Dr | 2005 |
Bioterrorism, public health, and international law.
Topics: Anthrax; Bioterrorism; Ciprofloxacin; Commerce; Communicable Disease Control; Criminal Law; Developi | 2002 |
An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
Topics: Adverse Drug Reaction Reporting Systems; Amoxicillin; Anthrax; Anthrax Vaccines; Anti-Bacterial Agen | 2005 |
Effective antiprotease-antibiotic treatment of experimental anthrax.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bacterial Proteins; Ciprofloxacin; Drug | 2005 |
Anthrax lethal factor inhibition.
Topics: Animals; Anthrax; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Ciprofloxacin; Crystall | 2005 |
[Evaluation of anthrax vaccination in Denmark].
Topics: Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Bioterrorism; Ciprofloxacin; Denmark; Humans; Safe | 2005 |
An unusually extensive case of cutaneous anthrax in a patient with type II diabetes mellitus.
Topics: Aged; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Ciprofloxacin; Diabetes Mellitus, Type 2; | 2005 |
Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
Topics: Administration, Oral; Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Bl | 2005 |
Comparison of clarithromycin and ciprofloxacin therapy for Bacillus anthracis Sterne infection in mice with or without (60)Co gamma-photon irradiation.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Cobalt; Drug Therapy, Combin | 2005 |
Newly developed colorimetric drug screening assay for Bacillus anthracis.
Topics: Anthrax; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Colorimetry; Coloring Agents; Doxycycline; | 2006 |
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax.
Topics: Administration, Inhalation; Animals; Anthrax; Anti-Bacterial Agents; Antibodies, Monoclonal; Antigen | 2006 |
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax.
Topics: Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Pr | 2006 |
Cutaneous anthrax as an occupational disease in Central Anatolia, Turkey.
Topics: Adolescent; Adult; Agriculture; Animals; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Baci | 2006 |
Anthrax meningoencephalitis successfully treated.
Topics: Aged; Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Brain Edema; Cefoperazone; Cerebrospinal F | 2007 |
Adverse events associated with prolonged antibiotic use.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anthrax; Anti-Bacteri | 2008 |
[Comparative evaluation of the effectiveness of fluoroquinolones in experimental anthrax infection].
Topics: Animals; Anthrax; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; Drug Evaluation, Pre | 1994 |
US fear of bioterrorism spreads as anthrax cases increase.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Fear; Florida; Humans; New York | 2001 |
UK doctors given guidance on dealing with anthrax.
Topics: Abattoirs; Anthrax; Anthrax Vaccines; Anti-Infective Agents; Ciprofloxacin; Health Personnel; Humans | 2001 |
Anthrax blamed as two postal workers die in United States.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Humans; Male; Occupational Diseases; Po | 2001 |
Bioterrorism. Researchers question obsession with Cipro.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antigens, Bacterial; Bacillus anthracis; Bact | 2001 |
War on terror. A run on antibiotics.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Drug Resistance, | 2001 |
Anthrax. Deadly delivery.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Humans; Respiratory Tract Infections; S | 2001 |
Protecting yourself.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Humans; Influenza Vaccines; Planning Te | 2001 |
Update: Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.
Topics: Adult; Aged; Anthrax; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Female | 2001 |
Post-exposure anthrax prophylaxis.
Topics: Abdominal Pain; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Anti-Infective Agents; Ba | 2001 |
Bayer cuts price of ciprofloxacin after Bush threatens to buy generics.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Drug Costs; Drug Industry; Drugs, Gener | 2001 |
Be a patriot. Don't hoard Cipro!
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Democracy; Humans; Social Values; Unite | 2001 |
Attempts to stem Anthrax fears stumble.
Topics: Adrenal Cortex Hormones; Anthrax; Bacillus anthracis; Bioterrorism; Centers for Disease Control and | 2001 |
Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Chi | 2001 |
Cutaneous Bacillus anthracis infection.
Topics: Adult; Anthrax; Anti-Infective Agents; Arm; Bacillus anthracis; Ciprofloxacin; Humans; Male; New Yor | 2001 |
Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
Topics: Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; B | 2001 |
Into the zone of the unknown. It's been the blind leading the blind through the maze of anthrax.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Centers for Disease Control and Prevention, U.S.; Cipr | 2001 |
What you should know. Confusion about anthrax and what to do about it abounds; here are answers, straight and up to date.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Diagnosis, Differential; Humans; Occupa | 2001 |
Clinical presentation of inhalational anthrax following bioterrorism exposure: report of 2 surviving patients.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Bioterrorism; Blood; Ciprofloxacin; Clindamycin; | 2001 |
Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.
Topics: Adult; Amoxicillin; Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bioterrorism; Breast Fee | 2001 |
Anthrax. A 'sure killer' yields to medicine.
Topics: Adult; Anthrax; Bacillus anthracis; Child; Ciprofloxacin; Clindamycin; Disease Susceptibility; Drug | 2001 |
Winter, plague and pestilence.
Topics: Anthrax; Bacillus anthracis; Biological Warfare; Bioterrorism; Ciprofloxacin; History, 19th Century; | 2001 |
Bioterrorism. Lessons learned so far.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Humans; Postal Service; Risk; Uncertain | 2001 |
From the Centers for Disease Control and Prevention. Investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001.
Topics: Adult; Aged; Anthrax; Anti-Infective Agents; Bacillus anthracis; Bioterrorism; Ciprofloxacin; Female | 2001 |
From the Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Chi | 2001 |
From the Centers for Disease Control and Prevention. Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Overlooked in Cipro hype: other anti-anthrax meds.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Doxycycline; Humans; Penicillins; Tetra | 2001 |
Ciprofloxacin frenzy.
Topics: Anthrax; Anti-Infective Agents; Ciprofloxacin; Drug Utilization; Internet; Pharmacies; Pharmacists | 2001 |
From the Centers for Disease Control and Prevention. Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis.
Topics: Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
From the Centers for Disease Control and Prevention. Recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.
Topics: Adult; Anthrax; Anti-Infective Agents; Antibiotic Prophylaxis; Bioterrorism; Breast Feeding; Child; | 2001 |
From the Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
TRIPS: generic irony.
Topics: Anthrax; Anti-HIV Agents; Anti-Infective Agents; Ciprofloxacin; Drug Industry; Drugs, Generic; HIV I | 2002 |
In shift, disease agency recommends combinations of antibiotics for anthrax cases.
Topics: Anthrax; Anti-Infective Agents; Centers for Disease Control and Prevention, U.S.; Ciprofloxacin; Dru | 2001 |
The generics--other drugs to combat anthrax are in ample supply.
Topics: Anthrax; Anti-Infective Agents; Ciprofloxacin; Drugs, Generic; Humans; United States | 2001 |
Post-exposure anthrax prophylaxis.
Topics: Amoxicillin; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Anti-Infective Agents; Child | 2001 |
Cutaneous anthrax.
Topics: Adult; Anthrax; Anti-Bacterial Agents; Anti-Infective Agents; Child; Ciprofloxacin; Doxycycline; Hum | 2001 |
Fast tracking drugs to patients. Drug approval agencies are frequently criticised for either being too slow or too fast.
Topics: Anthrax; Anti-Infective Agents; Bioterrorism; Ciprofloxacin; Drug Approval; Europe; Time Factors; Un | 2002 |
Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001.
Topics: Anthrax; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacillus anthracis; Bioterrorism; Ciprofloxa | 2001 |
Anthrax: ENT manifestations and current concepts.
Topics: Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Anti-Infective Agents; Bacillus anthracis; Ciprofl | 2002 |
Staying healthy. Playing chicken with our antibiotics. Overtreatment is creating dangerously resistent germs.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Campylobacter Infections; Ciprofloxacin; Drug Resistance, M | 2002 |
Anthrax and other microbial threats.
Topics: Anthrax; Anti-Infective Agents; Biological Warfare; Bioterrorism; Ciprofloxacin; Disease Outbreaks; | 2001 |
Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax.
Topics: Anthrax; Anti-Bacterial Agents; Bacillus anthracis; Centers for Disease Control and Prevention, U.S. | 2002 |
Active systemic anthrax infection or lingering anthrax infection of cerebrospinal compartment?
Topics: Anthrax; Bacillus anthracis; Bacteremia; Cerebrospinal Fluid; Ciprofloxacin; Humans; Prognosis; Seve | 2002 |